Kardigan (KARD) Stock Price, News & Analysis

Company Overview

Kardigan is a biotechnology company focused on developing medicines for cardiovascular and related diseases. Its research and development activities are directed toward conditions affecting the heart and circulatory system, areas where significant unmet medical needs remain.

The company’s business centers on advancing a pipeline of investigational therapies from discovery through clinical development and, potentially, commercialization. Specific product names, geographic operations and leadership information were not available from reliable public sources.

Key Stats

• Today's Range: $12.23 to $14.19
• 50-Day Range: $13.49 to $22.06
• 52-Week Range: $12.23 to $27.00
• Volume: 1.03 million shs
• Average Volume: 513,561 shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.25
• Consensus Rating: Moderate Buy

Kardigan Stock Analysis - MarketRank™

Kardigan scored higher than 63% of companies evaluated by MarketBeat, and ranked 296th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kardigan has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Kardigan has a consensus price target of $42.25, representing about 205.5% upside from its current price of $13.83.

Amount of Analyst Coverage

Kardigan has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Kardigan are expected to grow in the coming year, from ($3.41) to ($3.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kardigan is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kardigan is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.75% of the float of Kardigan has been sold short.

Short Interest Ratio / Days to Cover

Kardigan has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Kardigan has recently increased by 16.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kardigan does not currently pay a dividend.

Dividend Growth

Kardigan does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.04

News Sentiment

Kardigan has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Kardigan this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for KARD on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kardigan insiders have not sold or bought any company stock.

Percentage Held by Institutions

Kardigan has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KARD
• CIK: 2123613
• Web: www.kardigan.bio
• Phone: 415-573-3220
• Fax: N/A
• Employees: 241
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kardigan: $42.25
• High Price Target: $46.00
• Low Price Target: $37.00
• Potential Upside/Downside: +206.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.72
• Quick Ratio: 8.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 93,504,000
• Free Float: N/A
• Market Cap: $1.29 billion
• Optionable: N/A
• Beta: N/A